Loading
Ph-positive ALL is acute lymphoblastic leukaemia carrying the Philadelphia chromosome. It was once the worst kind and is now often the best-controlled, thanks to TKIs and blinatumomab.
BCR::ABL1-positive B-ALL, ~25% of adult B-ALL and rising with age. TKI (dasatinib or ponatinib) plus reduced-intensity chemotherapy or steroids alone induces remission in nearly all; PhALLCON showed ponatinib beats imatinib for MRD-negative remission (34.4% vs 16.7%); D-ALBA showed a chemotherapy-free dasatinib-blinatumomab regimen with 95% 18-month survival. Whether transplant in first remission is still needed for MRD-negative patients is the open question.
In plain words · The fusion that defines chronic myeloid leukaemia and a quarter of adult acute lymphoblastic leukaemia; the first cancer driver ever switched off by a pill.
Showing the target this term concerns: BCR::ABL1 (Philadelphia chromosome).
Shares Ponatinib, Asciminib, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Asciminib, Dasatinib, BCR::ABL1 (Philadelphia chromosome).
Shares Ponatinib, Asciminib, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Asciminib, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Ponatinib, Asciminib, Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL).
Shares Dasatinib, Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL), Imatinib.
Shares Ponatinib, Asciminib, BCR::ABL1 (Philadelphia chromosome), Acute lymphoblastic leukaemia.
Shares Transplant-free Ph-positive ALL for MRD-negative adults, Ponatinib.